Pathology Core

病理学核心

• 批准号: 10477224
• 负责人: James R Cook
• 金额: $ 14.48万
• 依托单位: MAYO CLINIC ARIZONA
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-19 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10477224
• 关键词: Accounting; Agreement; Ancillary Study; Benchmarking; Biological; Biological Assay; Case Study; Classification; Classification Scheme; Clinic; Clinical; Clonality; Consensus; Diagnosis; Diagnostic; Disease; Ensure; Evaluation; Fluorescent in Situ Hybridization; Follicular Lymphoma; Gold; Grant; Image; Immunohistochemistry; In Situ Hybridization; Individual; Institute of Medicine (U.S.); Institution; International; International Prognostic Index; Laboratories; Lymphoid; Lymphoma; Mantle Cell Lymphoma; Molecular Diagnosis; Molecular Diagnostic Testing; Molecular Genetics; Molecular Profiling; Morphology; Non-Hodgkin' s Lymphoma; Online Systems; Paraffin; Pathologic; Pathologist; Pathology; Pathology Report; Patient-Focused Outcomes; Patients; Phenotype; Prognosis; Public Health; Reporting; Research; Research Project Grants; Resources; Sampling; Sampling Studies; Scanning; Site; Slide; Southwest Oncology Group; Stains; System; Techniques; Testing; Tissue Microarray; Utilization Review; World Health Organization; accurate diagnosis; base; cooking; cost efficient; diagnosis standard; diagnostic accuracy; digital; digital imaging; experience; health goals; imaging platform; imaging system; leukemia/lymphoma; member; new technology; prognostic index; success; therapeutic target; therapy resistant; web based interface; whole slide imaging

The Pathology Core (Dr. Cook) will provide thorough central pathology review of all patient samples studied in Projects 1-4 of this grant, utilizing web-based e-pathology resources and providing additional ancillary testing analyses when required to arrive at a consensus diagnosis. Tissue microarrays will also be constructed from paraffin blocks for Projects 2 and 3, facilitating cost-efficient downstream analysis. Aim 1) To provide a system for central pathology review utilizing digital slide imaging. Central review by a panel of internationally recognized lymphoma experts has been one of the cornerstones of prior LLMPP studies. Each case is reviewed by four lymphoma pathology experts, and agreement by at least three pathologists defines a consensus diagnosis. For cases where an initial consensus is not reached, the cases are reviewed by the entire pathology committee together and a consensus diagnosis established by majority opinion. Web based e-pathology resources based in the Cleveland Clinic e-pathology center will be utilized by the Pathology Core to facilitate central review in a cost efficient manner. Routine sections and immunohistochemical stains will be scanned using an Aperio whole slide imaging system, and reviewing pathologists will be provided access to review their assigned cases through a web based interface. Aim 2) To complete ancillary studies as required to reach a final pathologic diagnosis. Additional ancillary testing may include immunohistochemical stains, fluorescence in situ hybridization (FISH) studies and/or lymphoid clonality testing, may be necessary in some cases to arrive at a definitive consensus diagnosis. Such testing, when requested by the pathologists performing central review, will be performed in the Cleveland Clinic research core laboratories which include 1 Ventana Discovery, 3 Ventana Benchmark XT, 2 Ventana Benchmark Ultra, and 1 Dako immunohistochemistry platforms. An extensive FISH menu and PCR clonality assays employing gold standard Euroclonality primer sets are also available. Aim 3) To facilitate individual research projects through construction of tissue microarrays. Tissue microarrays will be constructed from samples submitted for Projects 2 and 3. Dr. James Cook will serve as PI for the Pathology Core. Dr. Cook has extensive experience in central pathology review for multi-institutional studies, having been a member of the LLMPP lymphoma pathology committee and the SWOG lymphoma pathology committee since 2005. Dr. Cook is supported by a strong Research core group within the Cleveland Clinic Pathology and Laboratory Medicine Institute, including research technologists, project managers, accounting experts, and other administrative support. This Core will impact each of the Projects 1-4 in this grant by ensuring each case studied has been thoroughly vetted and providing a gold standard, consensus pathologic diagnosis

病理学核心（Dr. Cook）将对研究的所有患者样本进行全面的中心病理学审查， 本补助金的项目1-4，利用基于网络的电子病理学资源，并提供额外的辅助测试 在需要时进行分析，以达成共识诊断。组织微阵列也将从 项目2和3的石蜡块，促进具有成本效益的下游分析。（1）提供一个系统 用于使用数字载玻片成像的中心病理学审查。由国际专家小组进行的中央审查 公认的淋巴瘤专家一直是之前LLMPP研究的基石之一。每种情况下未被 由四名淋巴瘤病理学专家审查，并由至少三名病理学家达成一致意见， 共识诊断对于未能达成初步共识的案件， 整个病理学委员会一起和一个共识的诊断建立了多数意见。基于Web的 病理核心将利用克利夫兰诊所电子病理中心的电子病理资源 以符合成本效益的方式促进中央审查。常规切片和免疫组化染色将 使用Aperio全载玻片成像系统进行扫描，审查病理学家将获得 通过基于网络的界面审查分配给他们的案件。目标2）按要求完成辅助研究 才能得出最终的病理诊断其他辅助检测可能包括免疫组织化学染色， 荧光原位杂交（FISH）研究和/或淋巴克隆性测试，可能是必要的，在一些 病例达成明确的共识诊断。如果病理学家提出要求， 进行中心审查，将在克利夫兰诊所研究核心实验室进行，其中包括1个 Ventana Discovery、3个Ventana Benchmark XT、2个Ventana Benchmark Ultra和1个Dako 免疫组织化学平台。采用金标准的广泛FISH菜单和PCR克隆性测定 欧洲克隆性引物组也是可用的。目标3）通过以下方式促进个别研究项目 组织微阵列的构建。组织微阵列将从提交给项目的样本中构建 2和3 James Cook博士将担任病理学核心的PI。库克博士拥有丰富的经验， 多机构研究的中心病理学审查，已成为LLMPP淋巴瘤的成员 病理委员会和SWOG淋巴瘤病理委员会自2005年以来。库克博士得到了 克利夫兰临床病理学和实验室医学研究所内强大的研究核心小组，包括 研究技术人员、项目经理、会计专家和其他行政支持。这一核心将 通过确保研究的每个案例都经过彻底审查， 提供了一个黄金标准，一致的病理诊断